Medical device company SciBase said today it won FDA pre-market approval for its Nevisense device designed for the early detection of malignant melanoma. The Stockholm-based company’s device is indicated for use on cutaneous lesions with 1 or more clinical or historical characteristics of melanoma, for obtaining additional information when considering a biopsy, the company said. […]